EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective

Abstract

There is a need for effective medications to treat patients living with schizophrenia or bipolar I disorder (BD-I). LYBALVI®, a combination of olanzapine and samidorphan, was recently approved for the treatment of adults with schizophrenia or BD-I. We estimated the budgetary impact of adding LYBALVI to the formulary from Commercial, Medicaid, and Medicare perspectives in the United States (US).